Kornimate/medical-research-clean huggingface dataset:
quiremspheres observational study

Conditions: Liver, Cancer of, Non-Resectable

Summary: the main purpose of this study is to further assess treatment efficacy and safety after using quiremspheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for sirt and allocated to this treatment by a multidisciplinary tumor board.

liver tumors can be of primary (hepatocellular carcinoma, hcc) or metastatic (mainly from colorectal carcinoma, crc) origin. both hcc and crc are common causes of death from cancer worldwide. the overall incidence of hcc and crc remains high in developing countries and is steadily rising in most industrialized countries. available treatment options depend on the size, number, and location of tumors, on liver status, overall performance status and comorbidities, on patency of portal vein and presence of extrahepatic metastatic disease. they include surgical (liver resection, liver transplantation), systemic (e.g. chemotherapy, immunotherapy), ablative (thermal ablation, chemical ablation) and intra-arterial (chemoembolization, radioembolization) modalities. radioembolization, also known as selective internal radiation therapy (sirt) with microspheres containing a radiation-emitting isotope (yttrium-90 or holmium-166) delivers localized radiation in the vasculature around liver tumors with relatively limited concurrent injury to the surrounding normal/healthy tissue. yttrium-90 radioembolization is currently included in several guidelines (easleortc, esmo).

Eligibility criteria:
inclusion criteria: * patient with diagnosis of primary liver tumor or metastases in the liver from other primary cancers, allocated to sirt with quiremspheres® as decided by a multidisciplinary tumor board * patient is ≥ 18 years * patient has understood and signed written informed consent to data collection in the study exclusion criteria: * patient's refusal * local practice guidelines prohibiting the patient to receive sirt

Keywords: hepatocellular carcinoma,holmium-166,sirt,quiremspheres®
stimulating the cochlear apex without longer electrodes

Conditions: Deafness With a Cochlear Implant

Summary: the most common cochlear implant intervention provides an electrode array that stimulates less than half of the length of the cochlea, leaving the regions which represent lower frequencies in the normally functioning ear unstimulated. providing stimulation over the entire cochlea has the potential to improve speech understanding, sound quality, as well as spectral and temporal representation. increasing the length of the electrode array to cover a greater portion of the cochlea has many potential issues, including increased damage to the cochlea and probability of incomplete insertions. in this study, a new technique is being investigated that allows stimulation across the entire cochlear extent without increasing the length of the electrode array. the purpose of this study is to evaluate the benefit of the new technique on speech understanding outcomes. additionally, the study will investigate the new configuration to explore how the auditory system encodes temporal and spectral information.


Eligibility criteria:
inclusion criteria: * participants in this study must have already been evaluated at the nyu cochlear implant center as being eligible for a cochlear implant. * they must have decided to receive a cochlear implant manufactured by cochlear limited and have been diagnosed with a moderate to profound sensorineural hearing loss in the ear to be implanted. * individuals who have already been implanted with a cochlear implant manufactured by cochlear limited with or without this new approach may also participate in this study. exclusion criteria: * they are under the age of 18 * they have not been diagnosed with a moderate to profound sensorineural hearing loss in the ear to be implanted * have \>15 years of profound deafness * have not chosen to receive a cochlear implant manufactured by cochlear limited * are pregnant or plan to conceive within 6 months of consenting
effects of parmigiano reggiano on skeletal muscle damage in older adults

Conditions: Old Age; Atrophy; Inflammatory Response; Muscle Soreness

Summary: aging is associated with the loss of muscle mass and function (sarcopenia) and reduced tissue regenerative capacity. eccentric exercise (ecc) is a model of ret that can be used with the elderly, due to the ability of the muscle to combine high muscle strength production with low energy cost. ecc contractions are significantly more damaging to the muscles and produce greater muscle strength, for these reasons there is a greater risk of inducing muscle damage before the muscle is able to adapt. parmigiano reggiano (pr) has some peculiar bromatological characteristics. the proteins contained in it, and in particular the potentially bioactive peptide sequences, can rapidly provide the amino acids necessary to promote muscle growth and repair during exercise. furthermore, pr can be an important source of fatty acids, of which a significant amount of short-chain fatty acids (scfa) which are known to have important clinical effects on body composition and metabolic health and can have a systemic anti-inflammatory effect. therefore, the central hypothes is that pr consumed during ret can provide more energy substrates and improve muscle recovery. to date, no studies have studied its function on recovery from exercise nor in the elderly.


Eligibility criteria:
inclusion criteria: * age \>60 years old or \>18 and \< 30 years old * bmi \>18 and \<30 kg/m2 * stable body weight in the past 3 months * valid medical certifacate for practice of physical activity exclusion criteria: * diabetes or pre-diabetes as for ada guidelines * chronic diseases (cardiovascular, liver, respiratory, cancer, etc) * acute inflammatory status * regular practice of intense physical activity (\>2 sessions/week) * treatment with steroids in the past 3 months * regular use of \>50g/die of parmigiano reggiano
a novel mse score to predict rhcc patients

Conditions: HCC

Summary: develop and validate a novel scoring system based on pathological factors to predict the postoperative survival of patients with rhcc.patients with rhcc who underwent hepatectomy were recruited from two hospitals.exploring whether this scoring system is related to prognosis


Eligibility criteria:
inclusion criteria: * a diagnosis of ruptured tumor confirmed by enhanced computed tomography (ct) and/or abdominal magnetic resonance imaging (mri), * a diagnosis of hcc made by two experienced pathologists exclusion criteria: * extrahepatic hcc metastasis * death within 1 month after surgery
antithrombotic strategy based on clinical events and 4d-ct for patients after tavr

Conditions: Transcatheter Aortic Valve Replacement; Antithrombotic Therapy; Bioprosthetic Valve Thrombosis

Summary: this is a multicenter, open-label, randomized controlled study meant to test the superior efficacy of oral anticoagulation (oac) therapy versus single antiplatelet therapy (sapt) in patients after tavr. patients who accept successful tavr will be randomized to receive either the oac group (vitamin-k antagonists) or the sapt group (aspirin) for 6 months on a 1:1 ratio. after that, patients from both groups will be treated with single antiplatelet therapy (aspirin). all patients will be followed for 1 year to test the difference between net clinical benefits and bioprosthetic valve thrombosis diagnosed by 4d-ct.


Eligibility criteria:
inclusion criteria: * patients aged 18-85 years old with severe aortic stenosis; * successful tavr via femoral artery approach (varc 3 device success criteria); * implantation of self-expanding bioprosthetic valve; * be willing to give informed consent. exclusion criteria: * patients with anticoagulant indications, such as atrial fibrillation, intracardiac thrombosis, deep vein thrombosis, pulmonary embolism, history of mechanical valve implantation; * patients needed double antiplatelet therapy, such as acute myocardial infarction within one year, coronary stent implantation within 6 months, peripheral artery stent implantation within 3 months; * patients who received concomitant tavr and percutaneous coronary intervention; * patients with peptic ulcers or active bleeding or history of cerebral hemorrhage * patients with ischemic stroke or tia within 6 months; * patients with left ventricular ejection fraction \ 70mmhg) before discharge; * patients intolerant or allergic to aspirin or vitamin-k antagonists (warfarin); * patients with evaluated glomerular filtration rate \<15ml/min/m2 (cockcroft formula) or on dialysis; * patients with poor compliance, unable to complete the study and follow-up as required; * patients' life expectancy less than 1 year; * patients who already participated in other clinical trials (within the last 30 days).
adapting the diabetes prevention program for a developing world context

Conditions: Weight Loss

Summary: this study will examine whether an adapted version of \]he diabetes prevention program (dpp) can be effective when delivered by community health workers (chws) in a poor urban community in south africa. we will randomize existing groups that are part of an non-governmental organization's (ngo) chronic disease management program (anticipated cluster n = 54; anticipated individual n=540), to receive either the program or usual care (wait-list). the primary outcome analysis will compare percentage of baseline weight loss at y1 between the program and usual care; however, after y1 usual care participants will also receive the program and both groups will be followed for another year.


Eligibility criteria:
inclusion criteria: * member of participating partner ngo "health club" (members are medically stabilized individuals with diabetes mellitus or hypertension referred for disease and lifestyle management) * bmi greater than or equal to 25 kg per meter squared exclusion criteria: * unsafe level of blood pressure (greater than or equal to 160 (systolic) and greater than equal to 100 mm (diastolic)) at screening * elevated blood sugar (a1c greater than 11) at screening * being pregnant, breast-feeding or planning pregnancy within 2 years * chronic use of oral steroid medication * intellectual disabilities that would prevent ability to understand the program * not intending to stay in the health club over the next 2 years
registry study on cystic fibrosis in chinese children

Conditions: Cystic Fibrosis

Summary: this study is a multicenter, prospective cohort study of patients diagnosed with cystic fibrosis, the clinical information of recruited patients, including clinical manifestations, lung function, chest imaging, quality of life and other indicators, will be followed for 10 years.

all new cases of cystic fibrosis which was confirmed or probably diagnosed at each center from the beginning of the study are made the investigation of the clinical manifestations, sweat test and cftr mutations by the standard diagnostic process.then all the patients' following clinical data will be followed for 10 years (once per six month): clinical manifestations, lung function, chest imaging (once per year), quality of life and other indicators.

Eligibility criteria:
inclusion criteria: * age 0\~18 years old * any organ system symptoms consistent with cf, such as chronic sinopulmonary disease, gastrointestinal and nutritional abnormalities, obstructive azoospermia or having siblings with cf * cftr dysfunction indicated by elevated sweat chloride levels ≥60 mmol/l twice, or one sweat chloride levels ≥40 mmol/l plus presence of two pathogenic cftr mutations on different alleles * probable cf patients with sweat chloride levels among 40\~59 mmol/l plus with presence of 0-1 pathogenic cftr mutation * consent to provide the related clinical specimen to the certain hospital * the guardians of the patients fully understand the purpose of the study, volunteer their children to participate in this study and sign informed consent. exclusion criteria: * subject will be excluded if she or he has one of the following: * it is unable to provide complete medical records or the current condition can not accept the diagnosis process. * she or he does not agree to participate in the test.

Keywords: cystic fibrosis, chinese, children
lupus flares and histological renal activity at the end of the treatment (lufla)

Conditions: Lupus Nephritis

Summary: at this moment, the duration of the treatment in proliferative lupus nephritis has not been determined. almost 30 percent of patients in total remission during or after a treatment, will relapse in the first 5 years. the factors associated to renal relapses are not completly known. the investigators think that an histological control study performed to patient with complete remission for a year at the end of a 3 years treatment could help us to know which patients are going to relapse.


Eligibility criteria:
inclusion criteria : * patients between 18 and 70 years old with proliferative lupus nephritis * 3 years treatment with a 6 month induction therapy and 2 years and a half of treatment maintenence exclusion criteria : * membranous nephropaty * mesangial nephropathy * less than 3 years treatment * less than 1 year of complete remission

Keywords: lupus nephritis treatment renal biopsy in lupus lupus flare
alcohol in the treatment of obesity

Conditions: Obesity, Weight Loss, Alcohol Drinking

Summary: this pilot study looks at the relationship of moderate alcohol consumption on weight loss.

we hypothesize that individuals who consume a moderate amount of alcohol, such as a glass or two of wine daily, will lose more during a weight-reduction program than will those who do not, if equal calories are administered to both groups. the purpose of this pilot study is to look at the relationship of alcohol in weight loss. the current standard in weight loss programs is to eliminate alcohol from the diet. we propose to enroll 50 females enrolled at the structure house residential diet program in durham, north carolina. half or the subjects will receive 150 calories in the form of white wine, 3.5 ounce with lunch and 3.5 ounces with dinner. the other half of the subjects wil receive their 150 calories in their regular diet. all participants are asked not to consume any additional alcohol. participants will be weighed daily. the study lasts four weeks.

Eligibility criteria:
inclusion criteria: * age \>21, female, bmi ≥ 30, no history of substance abuse, prior alcohol use of at least one drink/week; exclusion: * pregnancy, breast feeding, previous history of alcohol abuse, liver disease.
safety and antiviral activity study of clevudine 30 mg qd in patients with hbeag(-) chronic hbv

Conditions: Hepatitis B

Summary: the purpose of this study is to determine safety and efficacy of 30mg daily dose of clevudine (l-fmau) at 24 weeks of treatment in chronic hbv infected patients with hbeag negative


Eligibility criteria:
inclusion criteria: 1. patients who were between 18 and 60, inclusive 2. patients with hbv dna levels 1 x 105 copies/ml within 30 days of baseline. 3. patients who were documented to be hbsag positive for \> 6 months (documentation of positive hbsag for the previous 6 months included previous laboratory reports showing hbsag positive at least 6 month ago or lab results showing igm anti-hbc negative and igg anti-hbc positive at screening). 4. patients who were hbeag negative and hbeab positive. 5. patients with alt levels which were in the range of ≥1.2 and \< 15 times the upper limit of normal (uln) and bilirubin levels less than 2.0 mg/dl, prothrombin time of less than 1.7 (inr), a serum albumin level of at least 3.5 g/dl. 6. women of childbearing potential with a negative serum (β-hcg) pregnancy test taken within 14 days of starting therapy. 7. patients who were able to give written informed consent prior to study start and to comply with the study requirements. exclusion criteria: 1. patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy. 2. patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for hbv infection. previous treatment with interferon that had ended less than 6 months prior to the screening visit. 3. patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. 4. patients coinfected with hcv, hdv or hiv. 5. patients with clinical evidence of liver mass or with alfa-fetoprotein \> 50 ng/ml 6. patients who were pregnant or breast-feeding. 7. patients who were unwilling to use an "effective" method of contraception during the treatment period and for up to 3 months after cessation of therapy. for males, condoms should be used. females had to be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using at least medically acceptable barrier method of contraception (i.e. iud, barrier methods with spermicide or abstinence) 8. patients with a clinically relevant history of abuse of alcohol or drugs. 9. patients with a significant gastrointestinal, renal, hepatic (decompensated), broncho-pulmonary, biliary diseases except asymptomatic gb stone, neurological, cardiovascular, oncologic or allergic disease. the patient with a benign tumor was excluded if judged by an investigator that the continuation of study would be interfered by benign tumor. 10. patients with creatinine clearance less than 60ml/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\]
sugar text: a randomized controlled trial of a text message intervention for women with diabetes in pregnancy

Conditions: Diabetes in Pregnancy; Gestational Diabetes; Texting Interventions

Summary: maternal diabetes in pregnancy can negatively impact fetal well-being and contribute to adverse pregnancy outcomes. much of the morbidity associated with diabetes in pregnancy can be minimized with tight glucose control. a number of studies in non-pregnant populations have highlighted the feasibility, acceptability and efficacy of text messaging interventions for improving diabetic compliance and control. this study will investigate whether a text messaging intervention is feasible and effective in an urban, diabetic, obstetric clinic and whether this intervention can improve compliance with diabetes care, glucose control and pregnancy outcomes. the study will also assess satisfaction with the intervention itself.


Eligibility criteria:
inclusion criteria: * pregnant women aged 18-50 years * planned delivery at hospital of the university of pennsylvania exclusion criteria: * gestational age greater than 34 weeks at initial visit in the penn perinatal diabetes program * women who are unable to read english as all text messages will be in english * women who do not have a cellular phone capable of receiving text messages as this is the study intervention
redesigning pediatric primary care obesity treatment: virtual house calls

Conditions: Obesity, Pediatric

Summary: this study examines a redesign of pediatric primary care overweight/obesity treatment, augmenting typical in-person visits with: (1) direct-to-patient video telehealth to tailor counseling advice to families, (2) that leverages certified health coaches as a part of the care team, and (3) creates skills building in real-time within the home environment.

investigators will recruit children with an elevated body mass index (bmi) (85th to \<99th percentile) and a parent. dyads will participate in a 24-week intervention with a total of 26 contact hours. dyads will participate in weekly education sessions for the first 12 weeks and bi-weekly sessions for the remaining 12 weeks. additionally, dyads will participate in weekly exercise sessions. assessments will consist of anthropometric measures, psychological surveys, and nutritional evaluations. assessments will be completed at baseline, 3-months and 6-months.

Eligibility criteria:
inclusion criteria: children: * ages 9-13 years * bmi 85th to \<99th percentile * must be a patient within health system pediatric primary care * must be english or spanish speaking parent: -must be english or spanish speaking exclusion criteria: children: * cannot have an emotional, social, or physical disability that would prevent them from participating in the protocol * non-english or non-spanish speaking * cannot have a medical condition resulting in unintentional weight gain (i.e. prader willi) * females cannot be pregnant * in addition, children will potentially be excluded from participation if they have a positive screen during an interview led pre-screening eating disorder questionnaire parent: -non-english or non-spanish speaking

Keywords: obesity house calls pediatric primary care virtual telehealth
pathophysiologic hemodynamics after primary unilateral total hip arthroplasty (tha)

Conditions: Orthostatic Intolerance; Orthostatic Hypotension; Postoperative Complications

Summary: incidence and pathophysiologic hemodynamics of orthostatic intolerance and orthostatic hypotension in patients undergoing unilateral tha

early postoperative mobilization is a cornerstone in the so-called fast track multimodal perioperative approach and is essential in preventing postoperative morbidity and reducing hospital length-of-stay. intact orthostatic blood pressure regulation is essential for early postoperative mobilization. however, early postoperative mobilization can be delayed due to postoperative orthostatic hypotension (poh) defined as a fall in systolic pressure \> 20 mmhg and/or diastolic pressure \> 10 mmhg or due to postoperative orthostatic intolerance (poi), characterized by dizziness, nausea, vomiting, blurred vision or syncope during mobilization. although these conditions are well-known clinical problems that can delay early mobilization, relatively few data are available on pathophysiological mechanisms and possible treatments. several prospective studies with standardized mobilization procedures have already established that the incidence of poi and poh after tha is 38-42% at 6 hours after surgery. previous studies on patients undergoing prostatectomy and tha have also demonstrated that attenuated vasopressor response and a concomitant reduction in cardiac output (co) and cerebral perfusion during postural changes after surgery contributes to poi and poh. strategies aiming to reduce the incidence of poi and poh by pain management, vasoconstrictive treatment with alpha-1 receptor agonist, optimized fluid management with goal-directed fluid therapy and reduction of surgical stress-response with pre-operative high-dose glucocorticoid did not solve the problem. the precise pathophysiological mechanisms of poi and poh remain to be elucidated and this is therefore the aim of the current prospective observational study.

Eligibility criteria:
inclusion criteria: * age 18-65 * written informed consent * patients that speak and understand danish * patients undergoing primary unilateral total hip arthroplasty in spinal anesthesia in standardized fast-track setting exclusion criteria: * alcohol and drug abuse * cognitive dysfunction * history of orthostatic hypotension * use of anxiolytic or antipsychotic drugs * use of opioids * use of following vasodilator antihypertensive drugs: beta-blockers, angiotensin converting enzyme inhibitors (acei), angiotensin 2 receptor blockers (arbs), calcium channel blockers * use of loop diuretics, thiazid diuretics and potassium-sparing diuretics * use of gabapentin * arrhythmias or heart failure * diabetes mellitus type i * diabetes mellitus type ii * history of following diseases in the autonomic nervous system: parkinson disease, multiple sclerosis, autonomic neuropathies * history of cerebral apoplexy or transitory cerebral ischemia * dementia * american society of anesthesiologists (asa) score ≥ 4

Keywords: orthostatic intolerance orthostatic hypotension